Supplements and Featured Publications
Research Efforts Are Underway for AL Amyloidosis
Volume: 1
Issue: 1
Novel Therapeutic Approaches to Target PI3K Mutations in HR+/HER2– Breast Cancer
Volume: 1
Issue: 1
My Treatment Approach: Utilizing Test Results to Inform Clinical Decisions in NSCLC
Volume: 1
Issue: 1
Research Underway for MYC-Amplified Relapsed or Refractory Solid Tumors
Volume: 1
Issue: 1
2023 Genitourinary Cancers Symposium Meeting Reporter
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5